While VTN is overexpressed in GBM, it is also widely present in normal tissue and successful targeting strategies would need to differentiate tumour-associated VTN from circulating or stromal VTN, through methods such as genetically engineering T cell function to be restricted in the brain27. Here, VTN is linked to glioblastoma.